Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Beam Therapeutics Inc
(NQ:
BEAM
)
24.40
-2.28 (-8.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Beam Therapeutics Inc
< Previous
1
2
Next >
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
August 08, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Verve Therapeutics Gains 20.74% In June as Ark Funds Invest
June 30, 2023
Verve Therapeutics' efforts to eliminate cardiovascular disease through gene-editing treatments have momentum, as the stock gets a 20.74% boost in June.
Via
MarketBeat
Beam Therapeutics to Participate in Upcoming May Investor Conferences
May 17, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 11, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
May 10, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
March 27, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
March 21, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
March 15, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
March 01, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
February 28, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
February 07, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
January 09, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant
December 10, 2022
Data from ESCAPE-1 and ESCAPE-2 Approaches to Be Presented During Poster Sessions at the 64th ASH Annual Meeting and Exposition
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
December 02, 2022
Beam Ranked No. 4 in Large Companies Category, Marking Fourth Consecutive Year as Top Workplace in Massachusetts
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
December 02, 2022
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
November 30, 2022
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
November 14, 2022
BEAM-101 BEACON Trial Represents the First Clinical Trial of a Base Editor in the United States
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Participate in Upcoming Investor Conferences
November 09, 2022
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Beam Therapeutics
Via
GlobeNewswire
Beam Therapeutics to Present New Preclinical Data Highlighting Non-Genotoxic Conditioning Regimens for Patients with Sickle Cell Disease Ahead of Autologous Transplant at the 64th ASH Annual Meeting
November 03, 2022
From
Beam Therapeutics
Via
GlobeNewswire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
August 03, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Beam Therapeutics Inc. with Losses of $100,000 to Contact the Firm
August 02, 2022
From
The Schall Law Firm
Via
Business Wire
Hold Pfizer Today With Catalysts for Further Growth Tomorrow
July 18, 2022
Pfizer stock is down 12% in 2022. However, there is one short-term and one long-term catalyst that should inform your decision on whether PFE stock is right for your investment objectives.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
January 10, 2022
From
Pfizer Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.